Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure

Next Previous
X
Search
Trial Profile

A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JVS 100 (Primary)
  • Indications Chronic limb-threatening ischemia; Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STOP-HF
  • Sponsors Juventas Therapeutics

    • Most Recent Events

    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 26 May 2015 Results published in a Juventas Therapeutics media release.
    • 26 May 2015 Final results presented at the European Society of Cardiology - Heart Failure 2015, according to a Juventas Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top